1. Home
  2. SWX vs BCTXW Comparison

SWX vs BCTXW Comparison

Compare SWX & BCTXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWX
  • BCTXW
  • Stock Information
  • Founded
  • SWX 1931
  • BCTXW N/A
  • Country
  • SWX United States
  • BCTXW Canada
  • Employees
  • SWX N/A
  • BCTXW 18
  • Industry
  • SWX Oil & Gas Production
  • BCTXW Biotechnology: Pharmaceutical Preparations
  • Sector
  • SWX Utilities
  • BCTXW Health Care
  • Exchange
  • SWX Nasdaq
  • BCTXW Nasdaq
  • Market Cap
  • SWX N/A
  • BCTXW N/A
  • IPO Year
  • SWX N/A
  • BCTXW N/A
  • Fundamental
  • Price
  • SWX $73.62
  • BCTXW $0.29
  • Analyst Decision
  • SWX Hold
  • BCTXW
  • Analyst Count
  • SWX 3
  • BCTXW 0
  • Target Price
  • SWX $73.67
  • BCTXW N/A
  • AVG Volume (30 Days)
  • SWX 244.0K
  • BCTXW N/A
  • Earning Date
  • SWX 11-06-2024
  • BCTXW N/A
  • Dividend Yield
  • SWX 3.37%
  • BCTXW N/A
  • EPS Growth
  • SWX N/A
  • BCTXW N/A
  • EPS
  • SWX 2.50
  • BCTXW N/A
  • Revenue
  • SWX $5,209,839,000.00
  • BCTXW N/A
  • Revenue This Year
  • SWX N/A
  • BCTXW N/A
  • Revenue Next Year
  • SWX $0.06
  • BCTXW N/A
  • P/E Ratio
  • SWX $29.44
  • BCTXW N/A
  • Revenue Growth
  • SWX N/A
  • BCTXW N/A
  • 52 Week Low
  • SWX $57.03
  • BCTXW N/A
  • 52 Week High
  • SWX $79.03
  • BCTXW N/A
  • Technical
  • Relative Strength Index (RSI)
  • SWX 50.46
  • BCTXW N/A
  • Support Level
  • SWX $71.03
  • BCTXW N/A
  • Resistance Level
  • SWX $74.91
  • BCTXW N/A
  • Average True Range (ATR)
  • SWX 1.79
  • BCTXW 0.00
  • MACD
  • SWX -0.17
  • BCTXW 0.00
  • Stochastic Oscillator
  • SWX 32.40
  • BCTXW 0.00

About BCTXW BriaCell Therapeutics Corp. Warrant

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Share on Social Networks: